ProteinQure uses artificial intelligence and physics-based methods for the computational design of de-novo protein therapeutics. Antibodies, peptides, and other protein-based drugs are capable of targeting a broad range of biological targets outside the scope of traditional small molecule therapeutics. Due to their structural complexity, size and dynamic flexibility, computational methods for biologics are just now becoming possible. Our computational platform enables the world leading drug discovery companies to advance their early stage programs and is less data dependent than the alternatives.
You will receive a quarterly newsletter.
Welcome to computational protein drug design.
We are unlocking the potential of protein-based therapeutics
We design novel peptides (incl. cyclic and non-natural), antibodies and nanobodies.
We do not need large experimental data sets.
We optimize for any functional assay
with < 100 data points.
We don't sell software, we partner with
the world's largest pharma companies.
High-performance supercomputing, artificial
intelligence and molecular dynamics simulations.
ProteinQure has built the best computational platform for protein drug discovery. The computational platform combines high-performance computing, molecular simulations and machine learning to design and optimize small exotic protein therapeutics. These physics-based methods enable the structure-based design of protein drugs and make us less dependent on large data sets. This is relevant for novel chemical matter and difficult disease targets such as GPCRs, ion channels or intracellular protein-protein interactions).
We have three collaborations with top 25 pharma companies and have successfully validated our compounds in their experimental assays. The small proteins we specialize in are one of the fastest growing classes of therapeutics with applications across all major disease indications. We use our computational platform as well as wetlab validation to solve our drug design challenges and are now beginning to develop an internal pipeline.
We are not selling software, our partnership model involves upfront fees and milestones.
We engineer hits which are novel chemical entities. Our platform is designed to iterate with experimental results to save you time and money.
We perform iterative optimization of therapeutic leads to preserve properties like binding affinity, selectivity, stability and solubility. This multi-parameter optimization requires a search over vast areas of sequence space.
We engineer large protein libraries (for display methods) where every member incorporates computationally designed motifs.
Despite their inherent advantages, it is very difficult to design protein-based therapeutics.
Computational tools have been previously held back because of proteins' larger size and the lack of available structural data.
We leverage physics-based methods and novel machine learning algorithms to overcome these challenges.
Proteins can target a wider range of binding sites compared to small molecules. We work on difficult targets including GPCRs and intracellular targets.
Our therapeutics are engineered to be highly specific. Reducing unintended off target effects.
We engineer therapeutics with multiple binding epitopes. Helping to optimize new modalities.
We are located in downtown Toronto; one of the fastest growing tech hubs in North America. At the heart of the university and life sciences ecosystems, we benefit from great relationships with the surrounding players in AI and biotech.
Interested in learning more? Come talk to us!
Office Address: 119 Spadina Ave Suite 304, Toronto, ON M5V 2L1, Canada
E-Mail: team@proteinqure.com
Web: www.proteinqure.com
Show Google Map
